作者: Ali H. Ellebedy , Daved H. Fremont , Elitza S. Theel , Michael S. Diamond , Sean P.J. Whelan
DOI: 10.1016/J.CHOM.2021.01.014
关键词:
摘要: Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19 vaccines and have received emergency use authorization as therapeutics. However, viral …